Nabi And Roxane In Patent Dispute Over Kidney Dialysis Drug
Roxane sent Nabi a letter on August 8, 2005 informing the drug company that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration to make a generic version of PhosLo.
The lawsuit claims that “the letter did not provide the information specified by the FDA regulations. Nor did it demonstrate that the ‘665 patent is either invalid or would...
To view the full article, register now.